This company has been marked as potentially delisted and may not be actively trading. Vaccitech (VACC) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsInsider TradesTrendsBuy This Stock VACC vs. NLTX, CYBN, BIOA, VIRI, WHWK, PYRGF, OSTX, ATNM, EGRX, and NBRVShould you be buying Vaccitech stock or one of its competitors? The main competitors of Vaccitech include Neoleukin Therapeutics (NLTX), Cybin (CYBN), BioAge Labs (BIOA), Virios Therapeutics (VIRI), Whitehawk Therapeutics (WHWK), PyroGenesis Canada (PYRGF), OS Therapies (OSTX), Actinium Pharmaceuticals (ATNM), Eagle Pharmaceuticals (EGRX), and Nabriva Therapeutics (NBRV). Vaccitech vs. Its Competitors Neoleukin Therapeutics Cybin BioAge Labs Virios Therapeutics Whitehawk Therapeutics PyroGenesis Canada OS Therapies Actinium Pharmaceuticals Eagle Pharmaceuticals Nabriva Therapeutics Neoleukin Therapeutics (NASDAQ:NLTX) and Vaccitech (NASDAQ:VACC) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, risk, profitability, analyst recommendations, valuation, earnings and dividends. Which has higher valuation & earnings, NLTX or VACC? Vaccitech has higher revenue and earnings than Neoleukin Therapeutics. Neoleukin Therapeutics is trading at a lower price-to-earnings ratio than Vaccitech, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNeoleukin TherapeuticsN/AN/A-$57.56M-$3.11-7.00Vaccitech$13.42M4.02$5.34M-$1.43-0.98 Is NLTX or VACC more profitable? Neoleukin Therapeutics has a net margin of 0.00% compared to Vaccitech's net margin of -409.18%. Vaccitech's return on equity of -23.41% beat Neoleukin Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Neoleukin TherapeuticsN/A -37.22% -30.91% Vaccitech -409.18%-23.41%-20.85% Which has more risk and volatility, NLTX or VACC? Neoleukin Therapeutics has a beta of 1.11, indicating that its stock price is 11% more volatile than the S&P 500. Comparatively, Vaccitech has a beta of -0.4, indicating that its stock price is 140% less volatile than the S&P 500. Does the media prefer NLTX or VACC? In the previous week, Neoleukin Therapeutics' average media sentiment score of 0.00 equaled Vaccitech'saverage media sentiment score. Company Overall Sentiment Neoleukin Therapeutics Neutral Vaccitech Neutral Do institutionals & insiders believe in NLTX or VACC? 52.4% of Neoleukin Therapeutics shares are owned by institutional investors. Comparatively, 26.1% of Vaccitech shares are owned by institutional investors. 1.6% of Neoleukin Therapeutics shares are owned by company insiders. Comparatively, 6.0% of Vaccitech shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. SummaryVaccitech beats Neoleukin Therapeutics on 7 of the 10 factors compared between the two stocks. Get Vaccitech News Delivered to You Automatically Sign up to receive the latest news and ratings for VACC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VACC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VACC vs. The Competition Export to ExcelMetricVaccitechPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$53.97M$763.52M$5.48B$9.52BDividend YieldN/A4.84%4.73%4.08%P/E Ratio-0.981.3428.6723.80Price / Sales4.0225.20373.5466.64Price / Cash19.3019.5635.4557.96Price / Book0.216.778.275.55Net Income$5.34M-$4.28M$3.24B$259.03M Vaccitech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VACCVaccitechN/A$1.40-5.4%N/A-2.9%$53.97M$13.42M-0.9833Gap DownNLTXNeoleukin TherapeuticsN/A$21.68-4.6%N/A-46.3%$203.75MN/A-6.9790CYBNCybin2.5864 of 5 stars$7.30-3.6%$85.00+1,064.4%N/A$172.21MN/A-1.6750BIOABioAge LabsN/A$4.42-1.3%N/AN/A$160.61MN/A0.00N/APositive NewsVIRIVirios TherapeuticsN/A$4.82+1.0%$5.00+3.7%+2,247.1%$92.82MN/A-17.855Upcoming EarningsWHWKWhitehawk TherapeuticsN/A$1.79+1.1%N/AN/A$83.38M$25.98M11.1940PYRGFPyroGenesis Canada0.3773 of 5 stars$0.29-0.5%N/A-53.5%$53.95M$9.14M-4.8090News CoverageGap UpOSTXOS Therapies2.1036 of 5 stars$1.75-4.4%$18.00+928.6%N/A$49.17MN/A-2.03N/AATNMActinium Pharmaceuticals1.9811 of 5 stars$1.57-2.5%$4.00+154.8%-75.6%$48.98MN/A-1.1330News CoverageEGRXEagle Pharmaceuticals1.9805 of 5 stars$3.69flatN/A-33.3%$47.92M$257.55M0.00100Gap DownNBRVNabriva TherapeuticsN/AN/AN/AN/A$45.46M$35.59M0.0070 Related Companies and Tools Related Companies Neoleukin Therapeutics Competitors Cybin Competitors BioAge Labs Competitors Virios Therapeutics Competitors Whitehawk Therapeutics Competitors PyroGenesis Canada Competitors OS Therapies Competitors Actinium Pharmaceuticals Competitors Eagle Pharmaceuticals Competitors Nabriva Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VACC) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredOne stock to replace NvidiaI'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce compet...InvestorPlace | SponsoredA new rule goes live in July — and the banks are quietly crushing itA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vaccitech plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Vaccitech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
